| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0149-2918(96)80182-2 |
| P698 | PubMed publication ID | 8851456 |
| P2093 | author name string | R F Kaiko | |
| R F Reder | |||
| B Oshlack | |||
| D D Benziger | |||
| J B Miotto | |||
| P433 | issue | 1 | |
| P921 | main subject | bioavailability | Q461809 |
| P304 | page(s) | 95-105 | |
| P577 | publication date | 1996-01-01 | |
| P1433 | published in | Clinical Therapeutics | Q15716601 |
| P1476 | title | Steady-state bioavailability of controlled-release oxycodone in normal subjects | |
| P478 | volume | 18 |
| Q73206831 | A pharmacokinetic/pharmacodynamic study of controlled-release oxycodone |
| Q38006962 | A review of transbuccal fentanyl use in the emergency department. |
| Q99558026 | Bioavailability of oxycodone by mouth in coronary artery bypass surgery patients - a randomized trial |
| Q45821875 | Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control? |
| Q79970061 | Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study |
| Q51285178 | Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone. |
| Q42396049 | OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage form |
| Q64122126 | PharmGKB summary: oxycodone pathway, pharmacokinetics |
| Q35940208 | The changing landscape of opioid prescribing: long-acting and extended-release opioid class-wide Risk Evaluation and Mitigation Strategy |
Search more.